Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The guidance published on the Medicines and Healthcare products Regulatory Agency (MHRA) website is broadly similar to arrangements laid out in a Brexit “no deal” document published last year.

UK MHRA approves eplontersen to treat adults with rare inherited nerve disease or polyneuropathy: United Kingdom Monday, April 7, 2025, 15:00 Hrs [IST] The Medicines and Healthcar ...

A full list of side effects can be found in the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC), available on the MHRA website within 7 days of approval. As with any ...

In 2023, a report by Lord James O’Shaughnessy found the UK had dropped from fourth to tenth as global contributors to ...

The MHRA has approved eplontersen (Wainzua) for treating adults with polyneuropathy associated with hereditary transthyretin ...